Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Gains from Sales and Divestitures (2020 - 2024)

Relay Therapeutics (RLAY) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $398330.0 as the latest value for Q4 2022.

  • On a quarterly basis, Gains from Sales and Divestitures rose 424.98% to $398330.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $398330.0, a 424.98% increase, with the full-year FY2022 number at $398330.0, up 424.98% from a year prior.
  • Gains from Sales and Divestitures was $398330.0 for Q4 2022 at Relay Therapeutics, up from $75875.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $579825.0 in Q4 2020 to a low of $75875.0 in Q4 2021.
  • A 3-year average of $351343.3 and a median of $398330.0 in 2022 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 86.91% in 2021, then soared 424.98% in 2022.
  • Relay Therapeutics' Gains from Sales and Divestitures stood at $579825.0 in 2020, then tumbled by 86.91% to $75875.0 in 2021, then skyrocketed by 424.98% to $398330.0 in 2022.
  • Per Business Quant, the three most recent readings for RLAY's Gains from Sales and Divestitures are $398330.0 (Q4 2022), $75875.0 (Q4 2021), and $579825.0 (Q4 2020).